Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey acquired 7,250 shares at $1.40 per share in an indirect interest between April 30 and May 3, increasing the number of
Full Story >>
Vote
+34